MSO Earnings 2026 Q1: Multi-State Operator Financial Results & Analysis

Executive Summary

The first quarter of 2026 marked a pivotal reporting period for U.S. multi-state cannabis operators (MSOs), with Green Thumb Industries leading a wave of earnings disclosures that revealed both resilience and mounting pressure across the sector. As state-licensed cannabis companies navigated their sixth year under federal prohibition, Q1 2026 results illuminated the industry's maturation amid compressed margins, intensifying competition, and the persistent burden of Internal Revenue Code Section 280E tax treatment. Green Thumb Industries released its quarterly update on May 18, 2026, joining Curaleaf Holdings, Trulieve Cannabis, Cresco Labs, and Verano Holdings in providing investors and stakeholders with critical visibility into operational performance, cash flow generation, and strategic positioning. The earnings season arrived against a backdrop of stalled federal reform efforts, state market saturation in key jurisdictions including California and Michigan, and growing investor scrutiny of path-to-profitability metrics. For operators, patients, investors, and policymakers, these quarterly results serve as the industry's most comprehensive health check—revealing which business models withstand regulatory headwinds and which markets offer sustainable growth trajectories.

Why MSO Earnings Matter

Multi-state operator earnings reports represent the single most important data source for understanding the $30 billion U.S. state-legal cannabis industry's financial health and trajectory. Unlike federally legal industries, cannabis operators cannot access traditional capital markets, making quarterly disclosures the primary mechanism for transparency and accountability. These reports directly impact approximately 428,000 full-time equivalent jobs across cultivation, processing, retail, and ancillary services as of early 2026, according to industry workforce analyses. For investors managing an estimated $15 billion in deployed cannabis capital, Q1 2026 earnings determined portfolio valuations, merger and acquisition activity, and capital allocation decisions. The five largest MSOs—Green Thumb Industries, Curaleaf Holdings, Trulieve Cannabis, Cresco Labs, and Verano Holdings—collectively operated more than 580 dispensaries across 32 states as of March 31, 2026, serving millions of medical patients and adult-use consumers. Revenue performance, EBITDA margins, and cash flow generation disclosed in these reports directly influenced wholesale pricing for thousands of smaller cultivators and processors dependent on MSO distribution networks. State regulators in jurisdictions including New York, Ohio, and Pennsylvania monitored MSO earnings for signals of market stability, tax revenue sustainability, and compliance with social equity commitments. Medical cannabis patients tracked these reports for indications of product availability, pricing trends, and operator solvency—particularly in states where a single MSO controlled significant market share. The Q1 2026 reporting cycle carried heightened significance as operators disclosed results following the first full quarter under Ohio's adult-use program launch and amid New York's continued market expansion.

Background and History: The Evolution of MSO Financial Reporting

The multi-state operator business model emerged between 2014 and 2018 as state-level legalization created opportunities for vertically integrated cannabis companies to scale across multiple jurisdictions. This section traces the development of MSO financial reporting from its origins through the Q1 2026 earnings cycle.

2014-2016: The Birth of Multi-State Operations

The MSO model crystallized following Colorado's January 2014 launch of adult-use sales and the subsequent legalization wave across Alaska, Oregon, Washington, and California. Early operators including Cresco Labs (founded 2013), Green Thumb Industries (founded 2014), and Curaleaf Holdings (founded 2010, expanded nationally 2014-2016) pursued strategies of acquiring state licenses across multiple markets to diversify regulatory risk and achieve economies of scale. These early-stage companies operated as private entities with limited financial disclosure obligations, reporting primarily to private equity backers and state regulators. The investment thesis centered on federal prohibition as a temporary condition—operators bet that multi-state footprints would position them as national leaders once federal legalization occurred. Initial capital came predominantly from high-net-worth individuals and family offices willing to accept illiquidity and regulatory uncertainty. Financial reporting during this period remained inconsistent, with operators using varied accounting standards and disclosure practices.

2018-2019: Canadian Exchange Listings and Standardized Reporting

A transformative shift occurred in 2018 when U.S. MSOs began listing on the Canadian Securities Exchange (CSE) to access public capital markets. Curaleaf Holdings completed a reverse takeover transaction in October 2018, listing on the CSE under ticker CURA. Green Thumb Industries followed in May 2018, Cresco Labs in December 2018, and Trulieve Cannabis in September 2018. These listings subjected operators to International Financial Reporting Standards (IFRS) and continuous disclosure requirements under Canadian securities law. The CSE listings enabled MSOs to raise hundreds of millions in equity capital through bought-deal financings and at-the-market offerings. Curaleaf raised $400 million in a January 2019 offering; Cresco Labs raised $100 million in March 2019. This capital fueled aggressive expansion through license acquisitions and facility construction. Quarterly earnings reports became standardized events, with operators disclosing revenue, gross profit, adjusted EBITDA, and operational metrics including store count, cultivation square footage, and same-store sales growth. The U.S. Securities and Exchange Commission (SEC) maintained its prohibition on cannabis company listings on U.S. exchanges due to the Controlled Substances Act's Schedule I classification of marijuana under 21 U.S.C. § 812. This forced U.S. investors to access MSO securities through over-the-counter (OTC) markets, creating liquidity challenges and limiting institutional participation.

2020-2021: Pandemic Performance and Peak Valuations

The COVID-19 pandemic paradoxically accelerated MSO growth as states designated cannabis retailers as essential businesses. Q2 2020 earnings revealed double-digit sequential revenue growth as consumers stockpiled products and new customers entered the market. Green Thumb Industries reported $119.6 million in Q2 2020 revenue, up 167.5% year-over-year. Curaleaf Holdings reported $117.5 million, up 142% year-over-year. This performance, combined with expectations of federal reform under the incoming Biden administration, drove MSO valuations to all-time highs in February 2021. Curaleaf Holdings reached a market capitalization exceeding $13 billion; Green Thumb Industries exceeded $11 billion. Quarterly earnings calls drew hundreds of institutional investors, and operators provided increasingly detailed guidance on expansion timelines, margin improvement initiatives, and paths to GAAP profitability. The 2021 peak also marked the height of merger and acquisition activity. Curaleaf acquired Grassroots for $830 million in July 2020; Cresco Labs acquired Bluma Wellness for $213 million in August 2021. Quarterly earnings became forums for announcing strategic transactions and defending premium valuations through growth narratives.

2022-2023: Margin Compression and Strategic Recalibration

The failure of federal reform legislation—particularly the stalling of the SAFE Banking Act and the MORE Act in 2022—triggered a sustained valuation decline. By December 2022, Curaleaf's market capitalization had fallen below $3 billion, an 80% decline from peak. Green Thumb Industries traded below $3 billion. Quarterly earnings reports shifted from growth narratives to profitability and cash flow generation. Operators faced simultaneous pressures: wholesale price compression in mature markets including California and Colorado, retail price competition from expanding store counts, and the persistent burden of Section 280E taxation, which disallowed ordinary business expense deductions and resulted in effective tax rates exceeding 70% for some operators. Q3 2022 earnings revealed the impact—Curaleaf reported adjusted EBITDA margin compression to 22% from 28% a year earlier; Trulieve reported margin decline to 31% from 38%. Management teams responded with cost reduction initiatives, facility consolidations, and strategic market exits. Cresco Labs announced the closure of underperforming cultivation facilities in California in Q4 2022. Curaleaf reduced headcount by approximately 220 positions in Q1 2023. Quarterly earnings calls became forums for defending strategic decisions and reassuring investors of long-term viability.

2024-2025: Market Maturation and Selective Expansion

The 2024-2025 period saw MSOs adopt disciplined capital allocation strategies focused on high-growth limited-license states. New York's adult-use market launch in late 2023 and Ohio's November 2024 adult-use approval created new expansion opportunities. Q1 2024 through Q4 2025 earnings revealed operators prioritizing these markets while retrenching in oversupplied jurisdictions. Green Thumb Industries reported opening seven new retail locations in New York and Ohio during 2025. Curaleaf disclosed $45 million in capital expenditures for New York expansion in Q3 2025 earnings. Quarterly results also revealed the impact of state market dynamics—Florida operators including Trulieve reported margin pressure from vertical integration requirements and wholesale restrictions, while Illinois operators benefited from limited license structures maintaining pricing power. The August 2024 Department of Justice proposal to reschedule cannabis to Schedule III under the Controlled Substances Act, published as a Notice of Proposed Rulemaking (NPRM) in the Federal Register, created expectations of Section 280E relief. However, the rescheduling process remained pending through Q1 2026, with an administrative law judge (ALJ) hearing scheduled but not completed. Quarterly earnings calls throughout 2025 featured extensive discussion of potential tax relief scenarios and their impact on profitability.

Q1 2026: The Current Reporting Cycle

The Q1 2026 earnings season commenced with Green Thumb Industries' May 18, 2026 disclosure. The reporting period covered January 1 through March 31, 2026—the first full quarter following Ohio's January 2026 adult-use sales launch and amid New York's continued retail expansion. Operators entered the quarter facing several key dynamics: wholesale price stabilization in California after years of decline, continued retail competition in mature markets, and uncertainty regarding federal rescheduling timelines. Investor expectations centered on three key metrics: revenue growth rates, adjusted EBITDA margin stability, and free cash flow generation. Analysts projected the top five MSOs would collectively report approximately $1.4 billion in Q1 2026 revenue, representing mid-single-digit sequential growth and high-single-digit year-over-year growth. The earnings cycle would reveal which operators successfully balanced growth investments with profitability imperatives in an environment of persistent federal prohibition.

Key Players in the MSO Landscape

The Q1 2026 earnings cycle involved five dominant multi-state operators, each with distinct geographic footprints, strategic priorities, and operational models.

Green Thumb Industries

Green Thumb Industries, headquartered in Chicago and trading on the Canadian Securities Exchange under ticker GTII, operated 95 retail locations across 15 states as of March 31, 2026. The company pursued a strategy emphasizing branded product development through its &RYE, Dogwalkers, and Beboe product lines, which generated approximately 40% of revenue through wholesale distribution to third-party retailers. Founder and CEO Ben Kovler maintained significant ownership, providing strategic continuity since the company's 2014 founding. Green Thumb's geographic focus included Illinois, where it operated 23 RISE dispensaries, and expanding positions in Pennsylvania, New York, and Ohio.

Curaleaf Holdings

Curaleaf Holdings, headquartered in Wakefield, Massachusetts, operated the largest retail footprint among MSOs with 151 dispensaries across 18 states as of March 31, 2026. The company's strategy emphasized retail density and vertical integration, with cultivation and processing facilities supplying its retail network. Executive Chairman Boris Jordan and CEO Matt Darin led the company through its 2018 public listing and subsequent aggressive expansion. Curaleaf's core markets included Florida, where it operated 72 locations, and New Jersey, Pennsylvania, and New York. The company also maintained international operations in Europe through its majority ownership of Four 20 Pharma, providing exposure to medical cannabis markets in Germany and the United Kingdom.

Trulieve Cannabis

Trulieve Cannabis, headquartered in Quincy, Florida, dominated the Florida medical and adult-use market with 196 retail locations as of March 31, 2026—representing approximately 55% of the state's dispensary count. CEO Kim Rivers led the company's Florida-focused strategy since its 2015 founding, later expanding into Pennsylvania, Arizona, and West Virginia. Trulieve's business model centered on vertical integration within Florida, operating large-scale cultivation facilities supplying its retail network. The company's Q1 2026 results would reveal the impact of Florida's competitive dynamics, including wholesale price pressure and the state's vertical integration requirements limiting third-party product sales.

Cresco Labs

Cresco Labs, headquartered in Chicago, operated 58 Sunnyside retail locations across 10 states as of March 31, 2026. The company distinguished itself through wholesale distribution strength, with branded products including Cresco, High Supply, and Good News generating approximately 50% of revenue through third-party retail channels. Co-founder and CEO Charles Bachtell emphasized a strategy of market leadership in Illinois, Pennsylvania, and Ohio while maintaining selective presence in Massachusetts, New York, and Florida. Cresco's Q1 2026 results would provide insight into wholesale market dynamics and the success of its branded product strategy.

Verano Holdings

Verano Holdings, headquartered in Chicago, operated 136 retail locations across 13 states as of March 31, 2026. The company pursued a balanced strategy between retail and wholesale, with branded products including Verano, Avexia, and Savvy generating significant third-party distribution revenue. Founder and CEO George Archos maintained significant ownership and strategic control. Verano's geographic focus included Illinois, Pennsylvania, Florida, and expanding positions in New Jersey and Connecticut. The company's Q1 2026 earnings would reveal the effectiveness of its market diversification strategy.

Legal and Regulatory Framework Governing MSO Operations

Multi-state operators navigate a complex legal landscape defined by federal prohibition under the Controlled Substances Act, state-level licensing regimes, and punitive tax treatment under Internal Revenue Code Section 280E. The Controlled Substances Act, codified at 21 U.S.C. § 801 et seq., classifies marijuana as a Schedule I controlled substance under 21 U.S.C. § 812(c), Schedule I(c)(10). This classification renders cannabis cultivation, distribution, and possession federal crimes punishable by imprisonment and fines, regardless of state law authorization. MSOs operate under the understanding that the Department of Justice exercises prosecutorial discretion not to enforce federal prohibition against state-compliant operators—a policy formalized in the 2013 Cole Memorandum and maintained through subsequent administrations despite the memorandum's 2018 rescission. Section 280E of the Internal Revenue Code, codified at 26 U.S.C. § 280E, prohibits businesses trafficking in Schedule I or Schedule II controlled substances from deducting ordinary business expenses for federal tax purposes. MSOs may deduct only cost of goods sold—direct cultivation and production costs—while marketing, rent, salaries, and other operating expenses remain non-deductible. This results in effective federal tax rates frequently exceeding 70% of gross profit, creating significant cash flow burdens. The August 2024 DEA proposal to reschedule cannabis to Schedule III would eliminate Section 280E applicability, but the rescheduling remained pending through Q1 2026. State-level regulatory frameworks vary significantly. Limited-license states including Illinois, Ohio, and New York restrict the number of cultivation and retail licenses, creating barriers to entry and supporting operator profitability. Open-license states including California, Michigan, and Oklahoma impose minimal numerical restrictions, resulting in market saturation and price compression. Vertical integration requirements in Florida mandate that cultivation license holders operate their own retail locations, limiting wholesale market development. Securities regulation creates additional complexity. The SEC's prohibition on listing cannabis companies on U.S. exchanges forces MSOs to list on the Canadian Securities Exchange and trade on U.S. over-the-counter markets. This limits institutional investor participation and creates liquidity constraints. Canadian securities law requires continuous disclosure under National Instrument 51-102, mandating quarterly financial statements, management's discussion and analysis, and material change reporting.

State-by-State Market Dynamics Reflected in Q1 2026 Earnings

MSO earnings reports reveal divergent state market conditions, with limited-license jurisdictions supporting profitability while oversupplied markets compress margins.

Illinois

Illinois maintained a limited-license structure with 185 adult-use dispensary licenses and 21 cultivation licenses as of March 31, 2026. The state's regulatory framework supported wholesale pricing power, with premium flower averaging $3,200 per pound wholesale in Q1 2026. Green Thumb Industries, Cresco Labs, and Verano Holdings each operated significant Illinois footprints, with the state representing approximately 25-30% of revenue for each operator. Q1 2026 results would reveal whether Illinois' pricing stability continued amid gradual license expansion under the state's social equity program.

Florida

Florida's medical cannabis program served approximately 890,000 active patients as of March 31, 2026, making it the nation's largest medical market by patient count. The state's vertical integration requirement and wholesale restrictions limited market dynamics to retail competition among vertically integrated operators. Trulieve Cannabis maintained dominant market share at approximately 40%, with Curaleaf Holdings, Verano Holdings, and Surterra Wellness competing for remaining share. Q1 2026 earnings would reveal the impact of continued retail expansion—Florida added 47 dispensaries in Q1 2026—on same-store sales and margin performance.

Pennsylvania

Pennsylvania's medical cannabis program operated under a limited-license structure with 50 grower/processor permits and 177 operational dispensaries as of March 31, 2026. The state's prohibition on vertical integration created a robust wholesale market, with operators including Cresco Labs, Curaleaf Holdings, and Green Thumb Industries generating significant wholesale revenue. Pennsylvania's high medical patient count—approximately 485,000 active patients—and premium pricing supported strong operator profitability. Q1 2026 results would provide insight into Pennsylvania's sustainability as adult-use legalization remained under legislative consideration.

Ohio

Ohio launched adult-use sales on January 7, 2026, following voter approval of Issue 2 in November 2023. The state's regulatory framework allowed existing medical dispensaries to commence adult-use sales immediately, creating a first-mover advantage for incumbent operators. Green Thumb Industries operated seven Ohio dispensaries, Cresco Labs operated five, and Curaleaf Holdings operated three as of March 31, 2026. Q1 2026 earnings would reveal the magnitude of Ohio's adult-use launch impact, with analysts projecting the state could generate $1.5-2.0 billion in annual adult-use sales at maturity.

New York

New York's adult-use program continued expanding through Q1 2026, with approximately 150 operational dispensaries as of March 31, 2026, up from 100 at year-end 2025. The state's Office of Cannabis Management prioritized social equity applicants for initial retail licenses, delaying large MSO retail expansion. However, operators including Curaleaf Holdings, Green Thumb Industries, and Cresco Labs maintained cultivation and processing operations supplying the wholesale market. Q1 2026 earnings would reveal wholesale revenue generation in New York and operators' retail expansion timelines as the state issued additional licenses.

California

California's oversupplied market continued challenging operators through Q1 2026, with wholesale flower prices averaging $800-1,000 per pound for premium product—down from $1,200-1,500 in 2024. The state's open-license structure resulted in more than 1,100 licensed cultivators and 1,000 retail locations as of March 31, 2026. Curaleaf Holdings and Cresco Labs maintained California operations focused on branded product wholesale distribution, while other MSOs reduced or exited California exposure. Q1 2026 earnings would reveal whether California wholesale pricing stabilized or continued declining.

Michigan

Michigan's adult-use market matured through Q1 2026 with more than 500 operational dispensaries and continued wholesale price pressure. The state's open-license structure and low barriers to entry created intense competition, with wholesale flower prices averaging $1,000-1,200 per pound. Green Thumb Industries operated three Michigan dispensaries, while other major MSOs maintained limited presence. Q1 2026 results would indicate whether operators viewed Michigan as a viable long-term market or a candidate for strategic exit.

Market and Business Implications

Q1 2026 MSO earnings carry significant implications for capital allocation, merger and acquisition activity, and wholesale market dynamics across the cannabis supply chain. For public market investors, earnings reports determine equity valuations and influence portfolio positioning. Operators demonstrating revenue growth, margin stability, and positive free cash flow generation attract capital, while those showing deterioration face selling pressure. The aggregate market capitalization of the top five MSOs stood at approximately $8.5 billion as of May 17, 2026, down from $12 billion at year-end 2025, reflecting investor caution ahead of earnings disclosures. Merger and acquisition activity depends heavily on operator cash flow generation and access to capital. Strong Q1 2026 results could enable operators to pursue acquisitions of smaller competitors in strategic markets, while weak results would force continued focus on organic operations. Analysts projected 2026 would see continued consolidation, with 15-25 significant transactions likely as smaller operators lacking scale faced profitability challenges. Wholesale pricing dynamics directly impact thousands of small and mid-size cultivators dependent on MSO distribution networks. MSO earnings reports revealing margin pressure often precede wholesale price reductions as operators seek to lower input costs. Conversely, strong retail performance and margin expansion can support stable wholesale pricing. Q1 2026 results would signal whether wholesale markets in key states including Illinois, Pennsylvania, and Ohio remained stable or faced renewed pressure. For debt investors, MSO earnings determine credit quality and refinancing risk. Several operators carried significant debt burdens—Curaleaf Holdings reported $575 million in long-term debt as of December 31, 2025; Cresco Labs reported $213 million. Strong Q1 2026 cash flow generation would support debt service and reduce refinancing risk, while weak results could trigger covenant concerns and increase borrowing costs. State tax revenue projections depend on MSO operational performance. Illinois collected $445 million in adult-use cannabis tax revenue in 2025; Pennsylvania collected $285 million in medical cannabis tax revenue. Q1 2026 earnings providing visibility into sales trends enable state budget offices to refine revenue forecasts and inform policy decisions on tax rates and license expansion.

What Industry Experts and Analysts Say

Cannabis industry analysts and institutional investors entered the Q1 2026 earnings season with cautious expectations, emphasizing the importance of margin stability and cash flow generation over revenue growth. According to research published by Viridian Capital Advisors in April 2026, analysts projected the top five MSOs would report aggregate Q1 2026 revenue of $1.38 billion, representing 6.2% sequential growth from Q4 2025 and 8.7% year-over-year growth. The research emphasized that revenue growth alone would not satisfy investors absent margin improvement and positive free cash flow. Cantor Fitzgerald equity research, in a May 2026 preview note, stated that investor focus would center on three key metrics: adjusted EBITDA margin performance, capital expenditure discipline, and same-store sales trends in mature markets. The research indicated that operators demonstrating adjusted EBITDA margins above 25% and positive free cash flow would likely see multiple expansion, while those below 20% margins would face continued valuation pressure. According to commentary from Poseidon Investment Management, a cannabis-focused investment firm, in April 2026, the firm expected Q1 2026 results would reveal a "barbell" dynamic—operators with strong positions in limited-license states including Illinois and Ohio would report solid performance, while those overexposed to California and Michigan would show continued challenges. The firm emphasized that geographic portfolio composition had become the primary determinant of operator success. Research from Stifel Financial Corp. published in May 2026 projected that Ohio's adult-use launch would contribute $35-50 million in incremental Q1 2026 revenue across the MSO sector, with Green Thumb Industries and Cresco Labs the primary beneficiaries given their Ohio retail footprints. The research noted that Ohio represented the most significant new market opportunity since New Jersey's adult-use launch in 2022. According to analysis from New Frontier Data, a cannabis market research firm, published in March 2026, the U.S. cannabis market reached $30.2 billion in total sales in 2025, with medical sales representing $8.1 billion and adult-use sales representing $22.1 billion. The research projected 2026 total market growth of 12-14%, driven primarily by new market launches in Ohio and continued expansion in New York, with mature market growth slowing to mid-single digits. Industry consultant and former MSO executive Emily Paxhia, speaking at the Benzinga Cannabis Capital Conference in April 2026, emphasized that Q1 2026 earnings would reveal which operators successfully transitioned from growth-at-any-cost strategies to disciplined capital allocation. According to Paxhia, operators demonstrating return on invested capital above 10% would separate themselves from competitors and attract institutional capital.

What's Next: Key Dates and Decision Points

The Q1 2026 earnings cycle extends through early June 2026, with several key dates and subsequent developments shaping operator trajectory through year-end. Green Thumb Industries released its Q1 2026 results on May 18, 2026, setting the stage for subsequent disclosures. Curaleaf Holdings scheduled its earnings release for May 20, 2026, followed by a management conference call. Trulieve Cannabis scheduled its release for May 22, 2026. Cresco Labs and Verano Holdings were expected to report by May 31, 2026, the deadline for Canadian-listed issuers to file quarterly financial statements under National Instrument 51-102. Beyond the immediate reporting cycle, several developments will shape MSO performance through the remainder of 2026. The DEA's administrative law judge hearing on cannabis rescheduling, initially scheduled for December 2025 but postponed, remained pending with no confirmed date as of May 2026. A final rule rescheduling cannabis to Schedule III would eliminate Section 280E tax treatment, potentially increasing MSO after-tax cash flow by 40-60% according to industry estimates. State-level developments include potential adult-use legalization in Pennsylvania, where legislation remained under consideration in the state legislature as of May 2026. Pennsylvania's transition to adult-use would create significant revenue opportunities for operators with existing medical operations. Florida's adult-use ballot initiative, qualified for the November 2026 ballot, could transform the nation's largest medical market into a dual-use market if approved by 60% of voters. Capital markets developments include potential uplisting to U.S. exchanges if federal reform occurs. The SAFE Banking Act, which would provide cannabis businesses access to traditional banking services and potentially enable U.S. exchange listings, remained under consideration in Congress as of May 2026. Passage would significantly improve MSO liquidity and institutional investor access. Operators will provide updated full-year 2026 guidance during Q1 earnings calls, offering visibility into expected revenue, EBITDA, and capital expenditure ranges. These guidance updates will shape investor expectations for Q2 2026 results scheduled for release in August 2026.

Further Reading and Primary Sources

• Green Thumb Industries Investor Relations: https://investors.gtigrows.com — quarterly financial statements, earnings presentations, and SEC filings
• Curaleaf Holdings Investor Relations: https://ir.curaleaf.com — financial reports and management commentary
• Trulieve Cannabis Investor Relations: https://www.trulieve.com/investors — quarterly results and corporate updates
• Cresco Labs Investor Relations: https://investors.crescolabs.com — financial disclosures and earnings materials
• Verano Holdings Investor Relations: https://verano.com/investors — quarterly reports and strategic updates
• Canadian Securities Exchange: https://thecse.com — real-time trading data and regulatory filings for CSE-listed MSOs
• U.S. Securities and Exchange Commission EDGAR Database: https://www.sec.gov/edgar — Form 6-K filings for foreign private issuers
• Internal Revenue Code Section 280E: 26 U.S.C. § 280E — full text of tax provision affecting cannabis businesses
• Controlled Substances Act: 21 U.S.C. § 801 et seq. — federal drug scheduling framework
• DEA Proposed Rescheduling Rule: Federal Register Vol. 89, No. 154 (August 2024) — Notice of Proposed Rulemaking for Schedule III reclassification
• Viridian Capital Advisors: https://www.viridianca.com — cannabis industry financial analysis and market research
• New Frontier Data: https://newfrontierdata.com — U.S. and global cannabis market sizing and forecasts
• Illinois Department of Financial and Professional Regulation: https://idfpr.illinois.gov/profs/adultusecan.html — state licensing data and regulatory updates
• Ohio Division of Cannabis Control: https://cannabis.ohio.gov — adult-use program implementation and license information
• New York Office of Cannabis Management: https://cannabis.ny.gov — retail license issuance and market development updates